

Pursuant to the provisions of article 227 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols reports its 2023 Consolidated Annual Accounts, including the Non-Financial Information Statement, with an unqualified opinion from its auditor KPMG.

These financials include the integration of the JV with ImmunoTek in accordance with IFRS 11 Joint Agreements, aligning the accounting treatment with the essence of the contract, which was amended for the last time in June 2023. For further information, please see *Note (10) Equity-Accounted Investees and Joint Business*.

Compared to the 2023 Condensed Consolidated Interim Financial Statements published on February 29, 2024, this integration does not impact the Profit and Loss Account, nor a material impact on key metrics including leverage ratio (which stands at 6.3x), or the Cash Flow Statement (positive impact of EUR 4 million), as shown below.

<i>(in million EUR)</i>	2023 Condensed Consolidated Interim Financial Statements <i>(publ. Feb. 29, 2024)</i>	Var.	2023 Consolidated Annual Accounts <i>(publ. Mar. 8, 2024)</i>
Non-current assets	14,893	96	14,989
Current assets	6,433	19	6,452
Total assets	21,326	115	21,441
Equity	8,011	(39)	7,972
Non-current liabilities	11,045	108	11,153
Current liabilities	2,270	46	2,316
Total equity and liabilities	21,326	115	21,441

In Barcelona, on 8 March 2024

Nuria Martín Barnés
Secretary to the Board of Directors